Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, November 1st, 2022.
Following the release, company management will host a webcast at 8:00 a.m. ET to discuss the Company’s financial results and business progress. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
Already registered? Access with your PIN here.
A live audio webcast can be accessed on the investors and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate, and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
Contact:
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.19 |
Daily Change: | 0.02 0.69 |
Daily Volume: | 5,919,683 |
Market Cap: | US$431.520M |
December 13, 2024 December 12, 2024 November 26, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB